Noida, Apr 30 (APAC Media): Boston-based investment firm Bain Capital’s arm, BC Investments IV Ltd, on Thursday offloaded shares worth around Rs 289 crore in Emcure Pharmaceuticals through a block deal on the open market, as per data available from the National Stock Exchange of India (NSE).
The transaction involved a sales transaction of nearly 18 lakh shares at an average price of Rs 1,608.20 apiece on April 29. Norges Bank, on behalf of the Government Pension Fund Global, acquired the stake.
Following the development, Emcure Pharma’s stock came under pressure, slipping nearly 3.75 per cent to an intraday low of Rs 1,665 during Thursday’s session.
The company informed exchanges that it will announce its audited standalone and consolidated financial results for FY26 on May 5, 2026.
Emcure reported a strong showing, with net profit rising 48 per cent year-on-year to Rs 231 crore, compared to Rs 156 crore in the corresponding period last year.
Revenue from operations also saw a 20 per cent increase, reaching Rs 2,363 crore.
Earnings per share stood at Rs 12.16, up from Rs 8.12 a year earlier.
The stock was trading at Rs 1,672.70 as of 2:30 pm on Thursday, down 3.6 per cent from the previous close of Rs 1,729.90.
Stock has delivered over 63 per cent returns over the past year and more than 18 per cent gains so far in 2026.
Emcure Pharma’s shares touched a 52-week high of Rs 1,768 on April 29, 2026, while the 52-week low stood at Rs 983 on May 9, 2025. The company’s market capitalization stood around Rs 31,611 crore.
Disclaimer: Views expressed are those of experts and do not reflect APAC Media. This is for informational purposes only, not financial advice. We are not responsible for investment decisions. Please consult a qualified financial advisor before investing.
Also Read:
Adani Ports Q4 Results: PAT Jumps 9% YoY to Rs 3,308 Crore, Revenue Up 26%; Declares Rs 7.5 Dividend
